66673-40-3 Usage
Description
5-Hydroxymethylpyrrolidin-2-one, also known as (R)-5-(Hydroxymethyl)-2-pyrrolidinone, is a 2-pyrrolidone derivative with therapeutic applications as a prostanoid receptor agonist. It is a chiral compound with a hydroxymethyl group attached to the 5-position of the pyrrolidinone ring, which plays a crucial role in its biological activity.
Uses
Used in Pharmaceutical Industry:
5-Hydroxymethylpyrrolidin-2-one is used as a prostanoid receptor agonist for the treatment of various medical conditions. It modulates the activity of prostanoid receptors, which are involved in a wide range of physiological processes, including vasodilation, bronchodilation, and platelet aggregation inhibition. This makes it a potential therapeutic agent for conditions such as cardiovascular diseases, respiratory disorders, and thrombotic disorders.
Additionally, 5-Hydroxymethylpyrrolidin-2-one can be used in drug development as a lead compound for the synthesis of other bioactive molecules with potential therapeutic applications. Its unique structure and functional groups allow for further chemical modifications to enhance its pharmacological properties and target specificity.
Check Digit Verification of cas no
The CAS Registry Mumber 66673-40-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,6,6,7 and 3 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 66673-40:
(7*6)+(6*6)+(5*6)+(4*7)+(3*3)+(2*4)+(1*0)=153
153 % 10 = 3
So 66673-40-3 is a valid CAS Registry Number.
InChI:InChI=1/C5H9NO2/c7-3-4-1-2-5(8)6-4/h4,7H,1-3H2,(H,6,8)/t4-/m1/s1
66673-40-3Relevant articles and documents
INHIBITORS OF APOL1 AND METHODS OF USING SAME
-
, (2020/07/14)
The disclosure provides at least one entity chosen from compounds of formula (I), solid state forms of the same, compositions comprising the same, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA
-
Page/Page column 53, (2020/10/09)
There is herein provided a compound of formula I or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, ring A, n and y have meanings as provided in the description.
LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS
-
, (2016/05/02)
Disclosed herein are compounds of formula (I) wherein L1, L2, L3, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.